Treatment Options For Proliferative Diabetic Retinopathy

Ahmed Hassan Aldghaimy, MD Head of Ophthalmology South Valley University


- By 2040 ,of the 600 million people worldwide with diabetes mellitus(DM) ,400-500 million will live in low -and middle income countries .Thus ,the impact of DM poses a substantial challenge to the health care systems in many developing countries .
- Diabetic retinopathy (DR) is a common and specific microvascular complication that develops over time .Severe stages of DR including proliferative diabetic retinopathy (PDR) and diabetic macular edema(DME) result in visual impairment and blindness without treatment.
- Although ME affected patients maintain, at least, ambulatory vision ,PDR ,on the other Hand, may result in severe vitreous hemorrhage or retinal detachment with hand movements vision or worse .


- An important pathogenic factor is the effect of chronic hyperglycemia on microvasculature and proinflammatory mediators
- This will lead to microvascular occlusion with the resultant ischemia and new vessel formation and microvascular leakage with the resultant retinal edema ,hemorrhage and exudates .


- Approximately 50% of patients with very severe NPDR progress to PDR within 1 year
- Proliferative vessels arise from retinal veins and often begin as a collection of multiple fine vessels
- NVD: when these vessels arise on or within one disc diameter of the optic nerve
- NVE: when they arise further on disc diameter

- These new vessels grow more easily on a preformed connective tissue framework. Thus, a shallowly detached vitreous face is a frequent site of growth of new vessels.
- The new vessels usually progress through a stage of further proliferation, with associated connective tissue formation.
- As PDR progresses, fibrous proliferation become either vascular or avascular.

```
1-clinically:
-symptoms
           -no symptoms
           -symptoms of blurry vision and floaters
-examination by
                -slit lamp biomicroscopy
                -indirect ophthalmoscopy
2-Diagnostic testing:
-fluorescein angiography
                      -locating areas of retinal ischemia
                      -differentiating IRMA and collaterals from NV
OCT:
      To evaluate for DME
     -to determine presence and extent of retinal tractions.
```







Treatment

1-Systemic :control of

a-DM

B-hypertension

2-Ocular:

A- non complicated PDR

1-scatter laser photocoagulation

2-intravitreal injections

B- complicated PDR :pars plana vitrectomy

1-non clearing vitreous hemorrhage

2-traction involving the macula

Retinal laser photocoagulation

```
Anaesethia:
           1-topical
           2-retrobulbar
Laser delivery:
               1-slit lamp
               2-indirect ophthalmoscopy
Sessions:
         1-one session
         2- multiple sessions
Wavelength:
            1-argon 532 n
            2-diode 810
Lenses:
       1-wide-field
```

2- three -mirror lenses



Laser parameters

-power:200mW

-duration:0.1 sec.

-spot size :500 um

-power is increased until whitening of the retina is achieved

- -if it is not possible to obtain a satisfactory burn with a power setting of 1 watt, a smaller or longer exposure time may be used.
- -laser burns are spaced one-half to one spot-width apart.
- -the burns are placed one disc diameter from the optic disc and the major temporal arcades.
- -approximately,1200-1800 laser burns are applied to the peripheral retinal tissue, actually focally destroying the outer photoreceptors and retinal pigment epithelium of the retina
- -large retinal vessels are avoided as are areas of preretinal hemorrhage.

Intravitreal injections

-the addition of anti-VEGF therapy or intravitreal steroid therapy aids in regressing and reducing preretinal and vitreous hemorrhage

-anti-VEGF therapy alone like:

=<u>DRCR.net</u> protocol S -intravitreal ranibizumab vs PRP

=CLARITY study
-intravitreal aflibercept vs PRP

-strong data demonstrates that anti-VEGF therapy for PDR is not inferior to PRP in terms of visual outcome at 2 years .

-indeed, it is associated with less visual field loss and less frequent development of DME.

Complicated PDR

Pars plana vitrectomy for: -

- non-clearing vitreous hemorrhage
- retinal tractions involving the macula

Thank You